BioChromatographix International (BCI), which recently launched in Singapore, is focusing on downstream processing with a new class of next-generation monolithic chromatography media for gene therapy, cell therapy, and advanced biologics manufacturing.
“At BCI, our mission is to revolutionize bioprocessing through precision-engineered monolithic chromatography solutions that deliver efficiency, scalability, and reliability. We are committed to empowering scientists and manufacturers with cutting-edge technologies that simplify workflows, accelerate discovery, and ensure quality at every step—driving forward the future of biomanufacturing,” according to Scott M. Wheelwright, PhD, co-founder and president of BCI.
“BCI products rely on axial flow and combine novel methacrylic materials with a proprietary monolithic architecture that provides highly reproducible results batch to batch and following scaleup,” he told GEN. “Convective flow chromatography has the potential to reduce the cost of production for viruses, plasmids, mRNA, and other biotherapeutics and vaccines.”
Chromatography has long been a cornerstone of bioprocessing, but many of today’s platforms are struggling to keep up with the scale, speed, and complexity required by modern biologics, continued Wheelwright.
Scott M. Wheelwright, PhD, co-founder and president of BCI
“We founded BCI to address those critical bottlenecks by introducing next-generation monolithic chromatography media that not only meet current needs but are built for the therapies of tomorrow. Our mission is to ensure that purification technologies evolve in step with innovation.”
“At BCI, we’re not just innovating in the lab. We’re building a platform for real-world impact,” noted Chervee Ho, co-founder and VP of Commercial Operations. “From day one, our focus has been on scalability, both in terms of our technology and our reach. We’re developing solutions that are commercially viable, globally available, and ready to integrate into existing biomanufacturing workflows. It’s about giving biotech companies the tools they need to grow faster and go further.”
“Purification has long been one of the most complex and limiting steps in the development of advanced therapies,” pointed out Alois Jungbauer, PhD, scientific advisor to BCI. “The innovation behind BCI’s monolithic media reflects a deep understanding of the real-world challenges in bioprocessing, particularly around flow dynamics, scalability, and emerging therapeutic modalities.”
BCI introduced its flagship platform, AXISFLOW
, a portfolio of solid monolithic columns designed for the purification of AAV, lentivirus, plasmid DNA, mRNA, exosomes, virus-like particles and bacteriophage.
Wheelwright brings over 30 years’ experience as a technical and business expert in biopharmaceuticals, pharmaceuticals, and related industries, particularly in the areas of manufacturing, process development, compliance, quality assurance and facilities. He previously held senior roles at Abbott, Chiron (now Novartis), and Scios (now J&J).
He co-founded two biotechs, BioInno Bioscience and Innovent Biologics in China. Wheelwright holds a PhD from UC Berkeley and was a visiting scholar at the Max Planck Institute.
“After over a decade in China helping build Innovent and BioInno, I moved to Singapore to co-found BCI with Chervee Ho, whose expertise in commercialization and regional strategy has been foundational to our early direction and momentum,” Wheelwright told GEN. “Singapore offers a uniquely supportive ecosystem for biotech startups, combining global connectivity, pro-innovation policies, strong IP protection, and ready access to quality suppliers and contract manufacturing.
“Beyond that, it’s a gateway to Asia’s diverse and rapidly growing markets. “Singapore is emerging as a central hub for next-generation biomanufacturing. It gives us a platform to build globally competitive technologies while staying agile and deeply connected to the region’s evolving healthcare needs.”
The post BioChromatographix International Officially Launches in Singapore appeared first on GEN - Genetic Engineering and Biotechnology News.
“At BCI, our mission is to revolutionize bioprocessing through precision-engineered monolithic chromatography solutions that deliver efficiency, scalability, and reliability. We are committed to empowering scientists and manufacturers with cutting-edge technologies that simplify workflows, accelerate discovery, and ensure quality at every step—driving forward the future of biomanufacturing,” according to Scott M. Wheelwright, PhD, co-founder and president of BCI.
“BCI products rely on axial flow and combine novel methacrylic materials with a proprietary monolithic architecture that provides highly reproducible results batch to batch and following scaleup,” he told GEN. “Convective flow chromatography has the potential to reduce the cost of production for viruses, plasmids, mRNA, and other biotherapeutics and vaccines.”
Bioprocessing cornerstone
Chromatography has long been a cornerstone of bioprocessing, but many of today’s platforms are struggling to keep up with the scale, speed, and complexity required by modern biologics, continued Wheelwright.
Scott M. Wheelwright, PhD, co-founder and president of BCI
“We founded BCI to address those critical bottlenecks by introducing next-generation monolithic chromatography media that not only meet current needs but are built for the therapies of tomorrow. Our mission is to ensure that purification technologies evolve in step with innovation.”
“At BCI, we’re not just innovating in the lab. We’re building a platform for real-world impact,” noted Chervee Ho, co-founder and VP of Commercial Operations. “From day one, our focus has been on scalability, both in terms of our technology and our reach. We’re developing solutions that are commercially viable, globally available, and ready to integrate into existing biomanufacturing workflows. It’s about giving biotech companies the tools they need to grow faster and go further.”
“Purification has long been one of the most complex and limiting steps in the development of advanced therapies,” pointed out Alois Jungbauer, PhD, scientific advisor to BCI. “The innovation behind BCI’s monolithic media reflects a deep understanding of the real-world challenges in bioprocessing, particularly around flow dynamics, scalability, and emerging therapeutic modalities.”
BCI introduced its flagship platform, AXISFLOW
Wheelwright brings over 30 years’ experience as a technical and business expert in biopharmaceuticals, pharmaceuticals, and related industries, particularly in the areas of manufacturing, process development, compliance, quality assurance and facilities. He previously held senior roles at Abbott, Chiron (now Novartis), and Scios (now J&J).
He co-founded two biotechs, BioInno Bioscience and Innovent Biologics in China. Wheelwright holds a PhD from UC Berkeley and was a visiting scholar at the Max Planck Institute.
“After over a decade in China helping build Innovent and BioInno, I moved to Singapore to co-found BCI with Chervee Ho, whose expertise in commercialization and regional strategy has been foundational to our early direction and momentum,” Wheelwright told GEN. “Singapore offers a uniquely supportive ecosystem for biotech startups, combining global connectivity, pro-innovation policies, strong IP protection, and ready access to quality suppliers and contract manufacturing.
“Beyond that, it’s a gateway to Asia’s diverse and rapidly growing markets. “Singapore is emerging as a central hub for next-generation biomanufacturing. It gives us a platform to build globally competitive technologies while staying agile and deeply connected to the region’s evolving healthcare needs.”
The post BioChromatographix International Officially Launches in Singapore appeared first on GEN - Genetic Engineering and Biotechnology News.